TFE3 and neoplasm: Accurate diagnosis, particularly the definitive molecular confirmation of ASPSCR1-TFE3 fusion, is paramount before initiating targeted therapies, as it ensures the correct patient population is selected, especially given the overlap in TFE3 positivity with other tumor types.